PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive: These drugs selectively inhibit aberrant kinases like BCR-ABL, c-KIT, and PDGFR, which are involved in the pathogenesis of cancers such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).